SLC5A2 and type 2 diabetes mellitus: The completion of multiple CVOTs for SGLT2 inhibitors and incretin-based therapies has indeed invigorated excitement in the field of cardiovascular endocrinology, as we now have data in tens of thousands of subjects with T2DM and high risk cardiovascular disease treated with these agents.